Infineon Cuts Chip Sales Guidance Amid Weak Personal-Electronics Demand
By Mauro Orru
Infineon Technologies lowered its sales forecasts for fiscal 2024 as the group reckons with months of weak demand for chips in personal electronics such as computers and smartphones.
The German chip maker said Tuesday that it is aiming for around 16 billion euros ($17.19 billion) in sales for the year ending in September, down about 2% from fiscal 2023. Its segment result margin--a key profitability metric--is expected in the low to mid-20s percentage range compared with 27% in fiscal 2023. The group had previously guided for roughly EUR17 billion in revenue and a segment result margin of about 24%.
Infineon posted revenue of EUR3.70 billion for the three months to the end of December compared with EUR3.95 billion in the previous year's fiscal first quarter.
Net profit slipped to EUR587 million from EUR728 million, while its segment result contracted to EUR831 million from EUR1.11 billion, generating a 22.4% margin.
Analysts had forecast revenue of EUR3.82 billion and a net profit of EUR549 million, with a segment result of EUR826 million, according to FactSet. Infineon had expected quarterly revenue of around EUR3.8 billion and a segment result margin of around 22%.
For the current quarter through March, Infineon expects revenue of roughly EUR3.6 billion and a segment result margin of about 18%.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
February 06, 2024 02:05 ET (07:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks